1. 10PPrognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer. (24th November 2019) Authors: Lim, S; Sohn, J; Kim, G; Moon, Y; Kim, J H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. (24th November 2019) Authors: Iwata, H; Im, S-A; Sohn, J; Jung, K H; Im, Y-H; Lee, K S; Inoue, K; Tamura, K; Wong, A; Emens, L A; Barrios, C H; Adams, S; Schneeweiss, A; Diéras, V; Winer, E P; Chui, S Y; Henschel, V; Rugo, H S; Loi, S; Schmid, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 38OTalazoparib (TALA) vs physician's choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA. (24th November 2019) Authors: Lee, K-H; Kim, S-B; Sohn, J; Goodwin, A; Usari, T; Lanzalone, S; Im, Y-H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 39OPooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET). (24th November 2019) Authors: Im, S-A; Yap, Y-S; Sohn, J; Lee, K S; Jung, K H; Tseng, L M; Lee, S C; Babu, K G; Park, Y H; Gounaris, I; Sondhi, M; Ridolfi, A; Zarate, J P; Lu, Y-S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗